ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.65
0.48%
US Tech 100
18,318.00
0.95%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36659
-0.02%
Bitcoin
69,048.99
0.79%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. LumiraDx Ltd (LMDX)

  7. LumiraDx Ltd (LMDX) News

LMDX

LumiraDx (LMDX)

LumiraDx Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LMDX
DateTimeSourceHeadlineSymbolCompany
01/05/20244:45PMGlobeNewswire Inc.LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thNASDAQ:LMDXLumiraDx Ltd
12/29/20234:07PMDow Jones NewsLumiraDx Agrees to Sell Point-of-Care Tech Platform to RocheNASDAQ:LMDXLumiraDx Ltd
12/29/20233:15PMGlobeNewswire Inc.LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheNASDAQ:LMDXLumiraDx Ltd
10/27/20233:45PMGlobeNewswire Inc.LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to AppealNASDAQ:LMDXLumiraDx Ltd
10/20/20235:34PMGlobeNewswire Inc.LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening HubNASDAQ:LMDXLumiraDx Ltd
08/24/20236:45AMGlobeNewswire Inc.LumiraDx Reports Second Quarter 2023 ResultsNASDAQ:LMDXLumiraDx Ltd
08/16/20233:30PMGlobeNewswire Inc.LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24NASDAQ:LMDXLumiraDx Ltd
07/31/20235:00AMGlobeNewswire Inc.LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and TestsNASDAQ:LMDXLumiraDx Ltd
06/30/20232:26PMDow Jones NewsLumiraDx Submits Dual FDA Medical Device Application for Covid-19 TestNASDAQ:LMDXLumiraDx Ltd
06/30/20231:30PMGlobeNewswire Inc.LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra TestNASDAQ:LMDXLumiraDx Ltd
06/20/20233:15PMGlobeNewswire Inc.LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV TestsNASDAQ:LMDXLumiraDx Ltd
05/16/20236:45AMGlobeNewswire Inc.LumiraDx Reports First Quarter 2023 ResultsNASDAQ:LMDXLumiraDx Ltd
05/09/20233:15PMGlobeNewswire Inc.LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16NASDAQ:LMDXLumiraDx Ltd
04/24/20233:21PMGlobeNewswire Inc.LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:LMDXLumiraDx Ltd
04/06/20238:20AMGlobeNewswire Inc.LumiraDx Announces Strategic Refocus and Cost Restructuring ProgramNASDAQ:LMDXLumiraDx Ltd
03/21/20236:26AMGlobeNewswire Inc.LumiraDx Reports Fourth Quarter and Full Year 2022 ResultsNASDAQ:LMDXLumiraDx Ltd
03/14/20237:03AMGlobeNewswire Inc.LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21NASDAQ:LMDXLumiraDx Ltd
03/03/20238:00AMGlobeNewswire Inc.LumiraDx to Present at Raymond James Institutional Investors ConferenceNASDAQ:LMDXLumiraDx Ltd
02/20/202310:00AMGlobeNewswire Inc.LumiraDx Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:LMDXLumiraDx Ltd
02/06/20237:59AMDow Jones NewsLumiraDx Gets FDA Emergency Authorization for Dual Flu-COVID TestNASDAQ:LMDXLumiraDx Ltd
02/06/20237:00AMGlobeNewswire Inc.LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular AssayNASDAQ:LMDXLumiraDx Ltd
01/31/20233:30PMGlobeNewswire Inc.LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UKNASDAQ:LMDXLumiraDx Ltd
01/31/20233:15PMGlobeNewswire Inc.LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:LMDXLumiraDx Ltd
12/14/20222:19AMGlobeNewswire Inc.LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis TestNASDAQ:LMDXLumiraDx Ltd
12/08/20222:01AMGlobeNewswire Inc.Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing CentersNASDAQ:LMDXLumiraDx Ltd
11/14/20228:44AMPR Newswire (US)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
11/14/20228:41AMPR Newswire (US)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
11/14/20228:41AMPR Newswire (Canada)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
11/14/20221:58AMGlobeNewswire Inc.LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
11/13/202210:05PMTipRanksLumiraDx (LMDX) Gets a Buy from BTIGNASDAQ:LMDXLumiraDx Ltd
 Showing the most relevant articles for your search:NASDAQ:LMDX

Your Recent History

LSE
ZX64
Cred Ag Co 30
ASE
ALTI
LSE
65FK
Comw.bk.a.nts35
COIN
ERCEUR
EU
BE0001797514
Region Wallonne 1.55% un...
LSE
HMSU
USOTC
YGWAF
Yokogawa Bridge (PK)
BIT
I06286
Banca Imi
KOSPI
007160
Sajo Industries
COIN
KGB2USD
COIN
UMXUST
UniMex Network
EU
BPCV
BPCE 1.45% 14jun2035
BIT
UB3JU5
UniCredit Bank
LSE
FR02
New Dev Bk.26
UPBT
STXBTC
Stacks
COIN
USDAUST
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved